Caribou Biosciences Reports $27.5 Million Net Loss in Q3 2025, Revenue Increases to $2.2 Million

Caribou Biosciences, Inc. reported a net loss of $27.5 million for the third quarter of 2025, a decrease from the $34.7 million loss recorded in the same period of the previous year. For the nine months ending September 30, 2025, the company experienced a net loss of $121.6 million, compared to a loss of $113.6 million for the same period in 2024. The company's total revenue for the third quarter was $2.2 million, up from $2.0 million in the prior year, while total revenue for the nine-month period decreased to $7.2 million from $7.9 million. The decline in nine-month revenue was primarily attributed to a decrease in revenue from the Edge chRDNA License Agreement, which had contributed $1.6 million in the previous year.

In terms of operational changes, Caribou has undergone significant restructuring, including the discontinuation of two clinical programs and a workforce reduction of approximately 32%, resulting in a cash severance cost of $1.8 million. The company also recorded impairment charges totaling $12.2 million for the nine months ended September 30, 2025, primarily related to leasehold improvements and lab equipment. These strategic decisions were made to prioritize resources towards the development of its lead product candidates, vispacabtagene regedleucel (vispa-cel) and CB-011, both of which are in clinical trials for hematologic malignancies.

As of September 30, 2025, Caribou's total assets were reported at $195.0 million, a significant decrease from $313.3 million at the end of 2024. The decline in assets was largely due to reductions in cash and cash equivalents, which fell to $11.1 million from $16.3 million, and a decrease in marketable securities. The company's total liabilities also decreased to $53.1 million from $60.4 million, reflecting a reduction in deferred revenue and other current liabilities.

Looking ahead, Caribou expects to continue incurring substantial losses as it advances its clinical trials and seeks regulatory approvals for its product candidates. The company reported that its existing cash, cash equivalents, and marketable securities of $159.2 million as of September 30, 2025, are anticipated to be sufficient to fund operations for at least the next 12 months. However, the company acknowledges the need for additional capital to support its ongoing development efforts and operational costs, emphasizing the uncertainty surrounding its ability to achieve profitability in the future.